BOEHRINGER EXEC BROUILLON TELLS REUTERS IT IS NOT CLEAR YET WHETHER SURVODUTIDE, CO-DEVELOPED WITH ZEALAND PHARMA, WILL FIRST BE LAUNCHED AGAINST LIVER DISEASE MASH OR OBESITY
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
657.5 DKK | -0.38% | +4.37% | +76.18% |
04-04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
03-20 | Zealand Pharma A/S Approves Appointments to the Board | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.18% | 5.9B | |
+2.94% | 108B | |
+9.09% | 105B | |
+0.55% | 23.46B | |
-14.34% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-7.81% | 17.19B | |
+5.49% | 13.99B | |
+37.04% | 12.53B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Boehringer Exec Brouillon Tells Reuters It Is Not Clear Yet Whet…